<unk> , sold under the brand name Enerzair Breezhaler among others, is an inhalable fixed-dose combination medication for the treatment of asthma. It contains indacaterol as acetate,<unk><unk> , and mometasone furoate. The most common side effects include worsening of asthma and nasopharyngitis (inflammation in the nose and throat). Other common side effects include upper respiratory tract infection (nose and throat infections) and headache. It is the first asthma triple-combination therapy; it consists of a fixed-dose combination of three active substances (indacaterol,<unk><unk>  and mometasone furoate) in capsules, to be administered using an inhaler. An optional electronic sensor may also be co-packed with the product. The sensor will be attached to the base of the inhaler to collect data on the use of the inhaler by the patient. The sensor will send the data to an app on a smart phone or other suitable device. It was approved for medical use in the European Union in July 2020.
Indacaterol/glycopyrronium bromide/mometasone
Indacaterol/mometasone
Olopatadine/mometasone
Drospirenone/estetrol
Finasteride/tadalafil
Relugolix/estradiol/norethisterone acetate
Dutasteride/tamsulosin
Mestranol/norethisterone